Last reviewed · How we verify
Atrovastain
Atorvastatin, developed by Assiut University, is a statin primarily used to manage hypercholesterolemia. It has completed Phase 4 trials in Korean adults and is exploring cardiotoxicity in acute myeloid leukemia. The drug has no FDA label but shows promise in lipid management.
At a glance
| Generic name | Atrovastain |
|---|---|
| Sponsor | Assiut University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Using of Atorvastatin for Anthracyclin _ Associated Cardiotoxicity in Hemetological Malignancies Patients. (Phase 1)
- Assessment of the Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia : A Multicenter, Prospective, Open-Label, Randomized, Trial (Phase 4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atrovastain CI brief — competitive landscape report
- Atrovastain updates RSS · CI watch RSS
- Assiut University portfolio CI